To develop a list of prescribing indicators specific for the hospital setting that would facilitate the prospective collection of high-severity and/or high-frequency prescribing errors, which are also amenable to electronic clinical decision support.
Introduction
Medication errors are relatively common in hospital practice and can lead to preventable patient harm [1] . Monitoring the types and rates of errors is crucial in understanding how processes can be improved to reduce the risk of patient harm, and to examine whether an intervention to improve a process has had the desired impact. Determining the potential harm of these errors and the subsequent burden to both the patient and the National Health Service (NHS) can prove difficult. Indeed many studies choose to utilize their own severity scales for defining a level of harm. These tend to be subjectively assessed and scored by the researcher and therefore introduce a degree of bias, or request consensus between a number of healthcare professionals for every error found in the research [2, 3] , which can prove time consuming and costly.
Untargeted prescription chart review for potential prescribing errors can lead to a plethora of low-or no-harm errors [3, 4] . Whilst newer processes exist for determining 'actual' harm occurrences -for example, by looking at triggers that indicate harms such as the prescribing of antidote drugs or critical laboratory values [5] -such processes require an intensive retrospective review of care records. Determining the preventable nature of such harm is also prone to subjective interpretation.
Prescribing indicators are agreed by a range of stakeholders to be a valid method to measure or monitor an area of prescribing, where there is a perceived direction in which the prescribing being measured should move over time [6] . Previous work in general practice has identified a list of critical indicators of potential prescribing errors in the UK as a means of assessing the safety of general practitioner (GP) prescribing [7] . In a similar manner, inappropriate prescribing (IP) criteria for older adults have been developed to facilitate chart review and identify the medications that may 'potentially' lead to adverse drug events [8, 9] . However, this 'screening' tool is restricted to errors of omission and commission, is specific to a patient population, and is not necessarily designed to measure prescribing over time. In Australia, hospitals are encouraged to use the 'Indicators for Quality Use of Medicines (QUM)' , which is a set of 30 indicators designed to measure both processes and outcomes of medication use to inform system improvement [10] . These indicators are generally not drug specific and capture data on quality rather than safety, looking, for example, at indicators for optimal medication use rather than indicators of potential harms. At present, therefore, there remains no validated list of 'prescribing' indicators that have been developed for the hospital setting or that are associated with both the highest risk of patient harm and likelihood of occurrence.
As Computerized Physician Order Entry (CPOE) becomes more widespread in the hospital setting, prescribing indicators should be amenable to being addressed by clinical decision support (CDS); that is, the error to which each indicator refers has the potential to be prevented by such software. Clinical decision support provides an opportunity to alert prescribers to potential harms [11] [12] [13] . Such systems have been shown to reduce medication error rates substantially, but most studies have not been powered to detect differences in the rate of adverse drug events [12] . The methods adopted by the researchers and the study outcomes also vary, making comparisons between them difficult. The development of indicators that are amenable to CDS allows for the effects of this technology to be quantified, which is not only important given the rate at which such technologies are being implemented but also relevant because of the heterogeneity of system configuration and complexity.
The aim of this research was to produce a list of prescribing indicators specific for the hospital setting that would aid the prospective collection of high-severity and/or high-frequency prescribing error data, in both paper-based and electronic medication processes.
Methods
The Delphi technique has been widely used in healthcare research as an approach to establish consensus in an area where published information is inadequate [8, 14] . This multistage methodology was selected to gather the subjective judgements of experts to develop and finalize a list of hospital prescribing indicators. We set out to complete an exploratory round, followed by two rounds of an eDelphi to identify high-or extreme-risk indicators with a consensus of at least 80% across an expert panel ( Figure 1 ).
Expert panel selection
Members of the research team (a pharmacist, clinical pharmacologist, epidemiologist and senior researcher in public health) selected participants based on their clinical expertise in medication safety, as well as those with knowledge of CPOE systems who would be able to identify errors that are amenable to reduction by CDS software. Some participants were recruited from a National Electronic Prescribing Conference (carried out as part of a Programme Grant to investigate prescribing safety in hospital ePrescribing systems) [15] , as well as personal contacts of the research team.
A total of 32 experts were invited to participate in the process, of whom 20 agreed. Panellists were pharmacists, clinical pharmacologists and physicians from geographically diverse areas in England, with a range of professional grades.
The eDelphi process
In the first instance, the research team defined inclusion and exclusion criteria for the prescribing indicators (see S. K. Thomas et al. Table 1 ). These criteria were used to construct an initial list of indicators based on clinical experience, searches of relevant UK resources and previous work conducted to define critical indicators of potential harm [8, [16] [17] [18] [19] [20] . Where possible, the original evidence base or language used by others to describe the issues was adopted to provide the context of the indicators. Each indicator was developed to state the trigger drug(s), the error process and the associated harm, in order to reduce the risk of misunderstanding and bias; for example, 'digoxin [drug] prescribed concomitantly [process] with a diuretic [drug] (risk of hypokalaemia and subsequent digoxin toxicity [harm])' . The prescribing indicators were summarized in a table and then circulated among the research team for comments and refinement before incorporation into a questionnaire for circulation to the participants for an exploratory round.
Exploratory round
The refined list of indicators was emailed to all participants enrolled in the study. They were asked to review each of the indicators and to recommend any modifications they deemed necessary. In addition, the opportunity was given for further indicators to be suggested that participants felt were missing from the initial list. The responses from this round were assessed by the research team, and those which had clinical merit were included in an updated list of indicators for round one of the eDelphi. A rationale for excluding suggested indicators was provided to each of the participants to give a clearer understanding of the overall inclusion criteria. For example, one participant suggested 'any use of naloxone or flumazenil' . The rationale provided to the participant stated 'this is a trigger to identify an adverse drug event, not an indicator of harm from a prescribing error' . 
Figure 1
A summary of the eDelphi process and results
Round one
Round one of the eDelphi aimed to identify the most clinically significant indicators, defined as those which would have the greatest risk in a clinical setting. Using a five-point Likert scale, participants were asked to rank each indicator for the likelihood of it occurring in hospital practice, and the severity of the most likely outcome should the error occur. This scale was based on that used by the UK National Patient Safety Agency, National Reporting and Learning Service (NRLS; see Table 2 ) [21] , and therefore one with which UK healthcare professionals were likely to be familiar. Acknowledging that participants' previous areas of clinical practice (e.g. oncology) may influence the scoring, they were requested to take a more general view in the interpretation of each indicator. When all ratings from round one had been received, the likelihood and severity scores were converted into 'risk scores' , using the NRLS Risk Matrix (Table 2 ) [21] . The median scores for each indicator were then calculated across the participants in the study, and the indicators divided into the following two groups: those where the median risk score was situated in the upper categories of 'high' or 'extreme' , and those where the risk was 'low' or 'moderate' . The degree of consensus between the participants was defined as the proportion that gave a risk score in the same group as the median. The mean consensus across all of the indicators was then calculated. The target for consensus was defined as at least 80%, in order to ensure that the resulting list of indicators was reliable. This adhered to validated consensus method for developing appropriateness scenarios [22] .
Round two In round two, the full list of indicators was returned to each participant, with their own individual scores for severity and likelihood shown, as well as the median scores from all members of the expert panel. This gave the opportunity for participants to modify their scores in light of the judgements of the rest of the group, or to retain their original viewpoints if they did not agree with the common opinion. The median risk scores were Table 1 Inclusion and exclusion criteria for the prescribing indicators Inclusion criteria:
• The indicator describes a drug prescribed in the general adult in-patient population • The indicator relates to a drug prescribed at a reasonable rate in the UK hospital environment Exclusion criteria:
• The indicator describes a prescribing practice that is not routinely undertaken in the UK hospital setting • The indicator is specific to a drug used in a patient population other than adult in-patients (i.e. paediatric vaccination schedules) • The indicator describes an error which would not be amenable to clinical decision support • Extraction of data required for the indicator (from hospital care records) is unlikely to be feasible • The indicator describes a failure to monitor treatment • The indicator describes errors relating to the dispensing or administration of a drug 
Results
The exploratory stage and two-round eDelphi were completed by all 20 participants. The expert panel consisted of 11 pharmacists with a sum of 122 years of hospital experience and nine physicians with a sum of 60 years of hospital experience (Table 3 ). All participants either worked in an academic institution or within an NHS hospital, and all had an interest in medication safety and/or electronic prescribing. In the first instance, 210 prescribing indicators were identified; 108 of these were from published studies using similar consensus techniques [8, 16, 17] , 36 from safety warnings and alerts from UK authorities [18] [19] [20] and 66 from clinical experience.
In the exploratory round, a refined list of 89 indicators was sent to the participants, and 71 additional prescribing indicators were suggested by the expert panel, of which 20 were selected for inclusion in round two (making a total of 109). The rationale for excluding 50 of the additional indicators is given in Table 4 .
A total of 80 of 109 prescribing errors were considered high or extreme risk by consensus when the scores for likelihood and severity were considered; these were included in the final screening tool (see Table 5 ). The indicators excluded in round two are summarized in Table 6 .
Of the 80 final indicators, the majority were synthesized from clinical experience (n = 25), followed by those identified by the STOPP/START (a screening tool of potentially inappropriate medicines or omission of appropriate medicines in the older adult population) criteria [8] Verapamil prescribed to a patient with NYHA Class III or IV heart failure (risk of precipitating heart failure, exacerbating conduction disorders and causing significant deterioration) Benzodiazepine or benzodiazepine-like drug prescribed to a patient with chronic obstructive pulmonary disease (risk of respiratory depression)
Central nervous system
Clinical contraindication 3 3 3 90%
Antipsychotic, other than risperidone, prescribed to a patient for the management of the behavioural and psychological symptoms of dementia (increased risk of stroke)
Clinical contraindication 4 3 3 100% Selective serotonin reuptake inhibitor prescribed to a patient with epilepsy (increased risk of seizure threshold being reduced)
Clinical contraindication 3 3 3 95%
Selective serotonin reuptake inhibitor prescribed to a patient with a history of clinically significant hyponatraemia (non-iatrogenic, sodium <130 mmol l -1 in the previous 2 months) (increased risk of hyponatraemia)
Prochlorperazine prescribed to a patient with parkinsonism (risk of exacerbating parkinsonism symptoms)
Clinical contraindication 3 3 3 80%
Nonsteroidal anti-inflammatory drug prescribed to a patient with chronic renal failure (increased risk of deteriorating renal function)
Nonsteroidal anti-inflammatory drug prescribed to a patient with a history of peptic ulcer disease or gastrointestinal bleeding without antisecretory drugs or mucosal protectants (increased risk of peptic ulceration and bleeding)
Nonsteroidal anti-inflammatory drug prescribed to a patient with a history of heart failure (risk of exacerbation of heart failure)
Clinical contraindication 3 3 3 85%
Lithium prescribed in conjunction with newly prescribed nonsteroidal anti-inflammatory drugs without dose adjustment or increased monitoring (increased risk of toxicity)*

Central nervous system
Drug-drug interaction 4 3 3 100%
Lithium therapy prescribed in conjunction with newly prescribed loop or thiazide diuretics without dose adjustment or increased monitoring (increased risk of toxicity)*
Central nervous system
Tricyclic antidepressant prescribed at the same time as a monoamine oxidase inhibitor (increased risk of serotonin syndrome)
Central nervous system
Drug-drug interaction 4 2 3 80%
Tramadol prescribed concomitantly with a monoamine oxidase inhibitor (increased risk of serotonin syndrome)
Central nervous system
Drug-drug interaction 4 2 3 84%
Selective serotonin reuptake inhibitor prescribed concomitantly with tramadol (increased risk of serotonin syndrome)
Drug-drug interaction 3 4 3 100%
Selective serotonin reuptake inhibitor prescribed concomitantly with aspirin without appropriate prophylaxis with antisecretory drugs or mucosal protectant (increased risk of gastrointestinal bleeding)
Drug-drug interaction 3 3 3 95%
Citalopram prescribed concomitantly with other QT-prolonging drugs (increased risk of arrhythmias)*
Central nervous system
Drug-drug interaction 3 3 3 85%
Tramadol prescribed concomitantly with antiepileptics (increased risk of seizures in patients with uncontrolled epilepsy)*
Central nervous system
Nefopam prescribed concomitantly with antiepileptics (increased risk of seizures in patients with uncontrolled epilepsy)*
Central nervous system
Drug-drug interaction 3 3 3 80%
Phenytoin and enteral feeds prescribed to a patient concomitantly (reduced absorption of phenytoin)
Central nervous system
Drug-food interaction 3 3 3 85%
More than one paracetamol-containing product prescribed to a patient at a time (maximal dose exceeded)
Duplicate therapy 4 3 3 95%
Benzodiazepines prescribed long term (i.e. more than 2-4 weeks) (risk of dependence and withdrawal reactions)
Central nervous system Duration 3 4 3 85%
Benzodiazepine or benzodiazepine-like drug prescribed long term to a patient with depression (risk of dependence and withdrawal reactions)
Central nervous system Duration 3 3 3 85%
Benzodiazepine-like drugs (e.g. zopiclone) prescribed long term (i.e. more than 2-4 weeks) (risk of dependence reactions)
Antipsychotic prescribed long term (i.e. >1 month) to a patient with parkinsonism (increased risk of worsening of extrapyramidal side-effects)
Regular opiates prescribed without concurrent use of laxatives (risk of severe constipation) †
Central nervous system
Omission of prophylactic treatment 3 4 3 85% The 80 indicators included a total of 41 different trigger drugs or classes, prescribed for the following indications: cardiovascular (n = 22), central nervous system (n = 28), endocrine (n = 5), gastrointestinal (n = 6), infection (n = 12) and miscellaneous (n = 7). The most common drugs and drug classes named in the indicators were antibiotics (n = 13), antidepressants (n = 8), nonsteroidal antiinflammatory drugs (n = 6), opioid analgesics (n = 6), antiplatelet medications (n = 5), methotrexate (n = 4), lowmolecular-weight heparins (n = 4), and benzodiazepine (and benzodiazepine-like) drugs (n = 4).
Prescribing of incorrect or inequivalent morphine (opiate) dose via multiple routes (risk of toxicity) †
Central nervous system
Participants identified five indicators as 'extreme risk' , calculated using the NPSA Risk Matrix. Three of these involved anti-infective drugs [macrolides (with warfarin), gentamicin and amphotericin B], one involved a lowmolecular-weight heparin and one related to paracetamol. The most frequent error types identified as high or extreme risk were those classified as clinical contraindications (n = 29 of 80). This included drugs prescribed in renal impairment (n = 8), heart failure (n = 4) and epilepsy (n = 4), as well as those that should be avoided with abnormal blood results (n = 4). Drug-drug interactions were the second most common error type (n = 23 of 80), with antidepressants being the most common interacting drug class (n = 5).
When indicators were ranked according to median severity scores only, only two indicators were given a score of '5' (catastrophic; see Table 2 ), as follows: amphotericin B prescribed without stating the brand name and the dose in milligrams per kilogram (risk of fatal overdose due to confusion between lipid-based and nonlipid formulations); and oral methotrexate prescribed to a patient with an inappropriate frequency (increased risk of toxicity).
Discussion
This eDelphi has identified 80 high-and extreme-risk prescribing indicators that are relevant to the hospital setting, which also have the potential to be prevented by alerts and warnings in decision support software. All 20 participants completed the exploratory round and both rounds of the eDelphi, removing any bias potentially introduced by missing responses from people with specific expertise.
The most frequently named drugs in the final list are antibiotics, opioids and low-molecular-weight heparins. This is consistent with the drugs and drug classes considered high risk by the NPSA, identified in incident reports with clinical outcomes of death and severe harm [23] . Opioid analgesics, antibiotics, warfarin and low-molecularweight heparins are the drugs with the highest percentage of medication incident reports with fatal and severe harm outcomes. Indicators relating to antidepressants were also frequent, but are not listed by the NPSA as drugs with a high number of reports for fatal and severe harm. Four of these were for selective serotonin reuptake inhibitors, a class of drug with a high prescribing rate in UK, with citalopram being one of the top 20 drugs dispensed by pharmacies in England [24] .
The most frequent error types associated with the indicators were clinical contraindications (n = 29 of 80) and drug-drug interactions (n = 23 of 80). In the USA, a set of high-priority drug-drug interactions were developed by an expert panel to help target CDS and create a list of interactions as a minimal standard for such systems [17, 25] . Interestingly, only six of the 23 drug-drug interactions identified by the expert panel in this eDelphi process were the same as those previously identified by Phansalkar et al. [17] , showing there to be a difference in opinion between what the UK and the USA would consider to be highly significant. This may, in part, be due to the difference in the rate at which these drugs are prescribed in each country. However, when the scoring for the indicators was ranked according to median severity scores only, two indicators scored '5' (catastrophic) and 26 scored '4' (major); nine of these were drug-drug interactions, and only one was consistent with the list defined by Phansalkar et al. [17] .
The prescribing indicators were developed for the hospital setting and therefore include some drugs which are not likely to be prescribed in general practice (e.g. *Additional indicators recommended by panellists in the exploratory round and included in round one (n = 13). †Indicators where the text was suggested to be modified by panellists in the exploratory round for round one (n = 2). Median risk scores are as follows: 1, low risk; 2, moderate risk; 3, high risk; and 4, extreme risk. Table 6 Indicators not considered high or extreme risk by consensus of at least 80%
Prescribing safety indicator title Proton-pump inhibitors prescribed at the same time as antacid formulations (reduced therapeutic effect of the proton-pump inhibitor)
Thiazide diuretic prescribed to a patient with a history of gout (increased risk of exacerbating symptoms in pre-existing gout) Thiazide prescribed to a patient with chronic kidney disease stage 3 (estimated glomerular filtration rate intravenous gentamicin). However, only six such indicators out of the 80 include drugs which would be prescribed only on an in-patient basis, and therefore 74 of the indicators have the potential to be applied to general practice. Indeed, eight of the final indicators were taken directly from Avery et al. [16] , which were originally developed for GP systems, and were subsequently scored as high or extreme risk in this eDelphi process. The indicators of harm identified provide an objective measure that can be implemented in the routine data collection of prescribing errors in both paper-based and electronic processes. The indicators can be identified during prospective prescription chart review, and their presence documented. Following the implementation of a safety improvement programme or intervention, it would be intended that the same prescription review process would be carried out (i.e. 'pre/post' studies). The collection of standardized data in this way allows for comparison to be made and conclusions drawn which can provide evidence for safety initiatives. With the capital cost of installing a CPOE system in a hospital being in the region of £1.5 million, research into its effect and effectiveness are crucially important. Investigating the rate of prescribing errors pre-and post implementation in such cases is beneficial in providing evidence to support one of the primary objectives of implementing such a system, i.e. to reduce the number of medication errors and subsequent harms.
The indicators are not restricted to one type of error, unlike similar studies [17] , and therefore include error types such as 'dosing' , which represent one of the largest error categories in the UK [23, 26] . The ability to capture a broad range of errors allows for more than one type of safety improvement strategy to be tested. Furthermore, the use of a standard data collection tool between hospital sites allows for valid comparisons to be made.
Finally, as a secondary outcome of this research, the indicators identified could be used to inform the development of decision support warnings or alerts, with the intention of minimizing untargeted or nonspecific alerting, which can lead to an overburdening of the prescriber and cause 'alert fatigue' , limiting its intended effects [27, 28] . A Cochrane review in 2011 found that point-of-care computer reminders generally achieve small-to-modest improvements in provider behaviour [29] , and concluded that further research must identify key factors -related to the 'target quality' problem or the design of the reminderthat reliably predict larger improvements in care from such expensive technologies. The indicators developed here can help to ensure that CDS targets the errors that are more likely to occur and/or have the greatest potential for causing patient harm, and may serve as a priority list for CDS software developers.
Limitations
Prior to the commencement of the eDelphi, 210 indicators were identified by the research team from both clinical experience and published literature. Of these indicators, 130 were excluded by the same members of the team because it was felt that they were neither prescribed at a reasonable frequency nor considered to be sufficiently high risk for inclusion. This review process meant that many of the indicators sent to the participants could already be considered high risk, and may explain why the final list was not substantially smaller. The same 20 participants also took part in both the exploratory round and the two-round eDelphi, which may further explain why consensus was reached on a large number of indicators. We acknowledge that there may also be a risk that in the original identification step we missed some high-risk errors, despite a robust review of the literature, or excluded some that other people would have considered important enough for inclusion. However, the exploratory round prior to the eDelphi process was designed to reduce the risk of such omissions in the final list.
All participants in the eDelphi were from geographically diverse areas in England. However, the lack of expertise from further afield may make this tool more specifically applicable to the UK setting. Indeed, it may be of interest to see whether, for example, experts from other defined geographical regions (e.g. USA and other European countries) would come to similar conclusions as UK healthcare professionals.
Finally, with the development of any indicator or trigger to monitor quality or safety in healthcare, its relevance should be continuously reviewed and updated. As new therapeutic agents are introduced and older ones go out of favour, the likelihood scores for their occurrence in clinical practice may well adjust, and they would no longer qualify according to our methodology.
Conclusions
Prescribing errors with high potential for causing patient harm have been identified by an expert panel. These indicators provide a standardized, validated tool for the routine collection of prescribing error data in both paperbased and electronic prescribing processes.They can serve as a means to assess safety improvement programmes preand post implementation, such as with the introduction of CPOE and CDS.This tool could also be of value in the refinement of alerts and warnings embedded within CPOE systems to ensure that they are targeted and that the alert burden on physicians is rationalized.
